HC Wainwright Reiterates “Buy” Rating for Black Diamond Therapeutics (NASDAQ:BDTX)

HC Wainwright restated their buy rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX) in a research report report published on Wednesday,Benzinga reports. They currently have a $11.00 price objective on the stock. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2024 earnings at ($0.31) EPS, FY2024 earnings at ($1.29) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.28) EPS.

Several other analysts have also recently weighed in on the company. Piper Sandler lifted their price target on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. Raymond James assumed coverage on Black Diamond Therapeutics in a report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $16.00 price target on shares of Black Diamond Therapeutics in a research report on Tuesday, October 8th.

Black Diamond Therapeutics Price Performance

BDTX stock opened at $3.29 on Wednesday. The stock has a market cap of $186.15 million, a price-to-earnings ratio of -2.47 and a beta of 2.51. The company has a fifty day moving average price of $4.10 and a two-hundred day moving average price of $5.00. Black Diamond Therapeutics has a one year low of $1.62 and a one year high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.09. Research analysts anticipate that Black Diamond Therapeutics will post -1.44 EPS for the current fiscal year.

Institutional Trading of Black Diamond Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC bought a new position in shares of Black Diamond Therapeutics in the third quarter worth $56,000. Vontobel Holding Ltd. bought a new position in Black Diamond Therapeutics in the 3rd quarter valued at about $68,000. Susquehanna Fundamental Investments LLC bought a new position in Black Diamond Therapeutics in the 1st quarter valued at about $82,000. SG Americas Securities LLC bought a new stake in shares of Black Diamond Therapeutics during the 2nd quarter worth approximately $108,000. Finally, Algert Global LLC bought a new stake in shares of Black Diamond Therapeutics during the 2nd quarter worth approximately $133,000. 95.47% of the stock is currently owned by institutional investors.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.